Financial Reports Latest Updates Industry Maps Economic Calendar

UroGen Pharma Ltd. (URGN) Annual Reports

Q: Where can I read UroGen Pharma Ltd. (URGN) annual reports?

Every year on this page links straight to the full text on SEC EDGAR. US annual reports are web pages (HTML) rather than PDFs, so you can read and search them in the browser. 3 filings are currently indexed.

Q: What is the difference between a 10-K and a 20-F?

A 10-K is the annual report of a US domestic issuer; a 20-F is filed by foreign private issuers (Taiwanese companies with US ADRs, such as TSMC, file 20-F). A 40-F applies to Canadian issuers under the MJDS.

UroGen Pharma Ltd. is listed on Nasdaq, classified by the SEC under Pharmaceutical Preparations (SIC 2834). This page indexes 3 annual reports, each linking to the full text on the SEC's EDGAR system.

Company profile

Exchange： Nasdaq
Fiscal year end： 12/31
SEC CIK： 1668243 →

Website：Official site ↗

Financial Highlights

FY2026 Q2 (quarterly, ended 2026-06-30)
	Current	Prior year	YoY
Revenue	$72.5M	$24.2M	+199.2%
Operating income	$111,000	$-41.4M	+100.3%
Net income	$-14.4M	$-49.9M	+71.3%

Company guidance
	Period	Range
Revenue	—	$97M – $101M

Figures are the company’s own outlook as stated in its earnings release, not analyst estimates.

Source: SEC EDGAR (XBRL company facts); guidance from Form 8-K Exhibit 99.1

Financial history

Revenue & profit

Quarterly · In mn (USD)

Revenue 72.5 mn Net income -14.3 mn

Show table：Income statement

Item	2015Q4	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Revenue	—	17.5	0.02	0	7.81	0.33	0.48	0.36	0.28	0	—	0.02	0	0	—	0.37	3.46	7.97	7.49	13.0	11.3	16.2	13.6	16.6	16.1	18.1	17.2	21.1	20.9	23.5	18.8	21.9	25.2	24.6	20.3	24.2	27.5	37.8	51.0	72.5
Gross profit	—	17.5	0	0	7.52	0.04	0.05	0.05	-0.77	0	—	0.02	0	0	—	0.32	3.15	7.31	6.59	11.6	10.1	14.6	12.0	14.8	14.1	15.8	14.9	18.7	18.5	21.2	17.1	19.6	22.8	22.1	17.9	20.7	24.2	34.5	46.8	65.9
Operating income	-12.4	0.8	-3.54	-5.95	-0.3	-10.2	-13.6	-18.4	-21.1	-24.0	-22.4	-23.8	-23.4	-39.8	-38.6	-31.8	-29.1	-27.3	-26.1	-22.8	-23.4	-19.9	-22.0	-18.7	-18.1	-20.3	-22.0	-15.4	-13.5	-14.6	-25.7	-25.8	-17.6	-27.7	-36.9	-41.5	-27.4	-19.1	-20.3	0.11
Net income	-12.7	-1.94	-3.42	-6.20	-0.3	-10.1	-13.4	-18.0	-20.5	-23.7	-21.4	-22.5	-22.3	-39.0	-37.8	-31.4	-28.8	-30.5	-25.9	-26.2	-30.2	-28.4	-28.4	-26.7	-25.8	-28.9	-30.2	-24.1	-21.9	-26.0	-32.3	-33.4	-23.7	-37.5	-43.8	-49.9	-33.4	-26.4	-23.6	-14.3

Balance sheet

Quarterly · In mn (USD)

Total assets 253 mn Total liabilities 385 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Show table：Balance sheet

Item	2015Q4	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Current assets	—	22.0	—	—	—	74.5	129	121	111	102	248	191	160	149	122	130	129	116	93.1	141	125	114	161	140	122	129	96.0	81.3	182	169	197	279	295	276	237	197	169	186	237	235
Total assets	—	23.1	—	—	—	75.5	129	122	113	104	252	239	227	202	167	161	140	122	97.4	154	135	120	166	146	128	136	113	95.4	194	178	201	282	302	286	248	209	185	200	254	253
Current liabilities	—	3.14	—	—	—	7.04	5.54	7.95	8.98	13.5	10.3	11.8	14.1	19.5	14.2	16.4	17.6	21.4	17.0	19.1	19.8	22.4	19.1	18.0	19.0	23.9	25.2	26.8	25.8	31.2	26.3	34.2	32.8	46.0	42.0	47.5	42.2	46.4	50.6	61.9
Total liabilities	—	6.75	—	—	—	7.04	5.54	7.95	8.98	13.5	12.5	13.8	15.8	22.1	16.5	18.4	19.4	25.6	20.9	97.5	103	111	183	187	192	225	230	234	236	244	241	252	276	295	294	302	300	306	378	385
Equity	16.3	16.3	13.2	74.1	76.3	68.5	124	114	104	90.1	240	225	211	180	150	143	121	96.4	76.5	56.3	31.5	8.41	-17.1	-40.9	-63.3	-89.4	-117	-138	-42.0	-65.2	-40.1	30.3	25.5	-8.80	-46.5	-93.4	-115	-105	-124	-132

Cash flow

Quarterly · In mn (USD)

Operating -33.0 mn Investing 1.67 mn Financing 0.5 mn

Positive = cash in, negative = cash out.

Show table：Cash flow statement

Item	2015Q4	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Operating	-7.17	4.19	-2.74	-3.46	2.60	-5.96	-9.62	-8.15	-9.28	-10.3	-17.9	-14.6	-12.5	-26.0	-35.6	-23.9	-25.1	-21.2	-27.4	-18.9	-18.5	-20.1	-24.0	-24.2	-17.6	-21.8	-25.8	-20.3	-17.3	-13.0	-31.7	-23.8	-27.7	-13.6	-42.0	-39.8	-42.3	-38.3	-45.3	-33.0
Investing	-0.3	-0.79	-0.08	-0.02	-0.12	-36.1	35.8	-0.18	-0.33	-0.03	-0.04	-142	-12.7	9.30	13.0	17.5	13.2	49.5	15.0	-30.7	10.7	9.13	13.6	-0.15	-35.5	23.1	6.27	3.72	0.4	-11.3	13.5	12.0	-107	60.6	-26.0	28.4	31.4	27.7	-20.7	1.67
Financing	21.6	-0.01	-0.11	62.1	-0.4	-0.06	64.3	-0.02	-0.01	2.20	164	0.37	1.13	0.25	0.09	16.3	0.06	0.08	0	72.5	-0.17	-0.03	70.7	-0.08	1.10	25.4	0.67	0.14	116	0.04	54.7	100	39.6	0.07	0.03	0.3	8.27	31.3	65.2	0.5
Cash at period end	18.0	21.4	18.4	77.1	79.2	37.0	127	119	109	101	247	90.4	66.2	49.7	26.5	36.4	24.6	52.9	40.5	63.3	55.3	44.4	105	80.7	28.7	55.4	36.5	20.1	119	95.0	131	220	125	172	104	92.9	90.0	111	110	79.1

Profitability

Quarterly · %

Gross margin 90.9% Operating margin 0.1% Net margin -19.8%

Gross, operating and net margin = the respective profit ÷ revenue.

Show table：Profitability

Item	2015Q4	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Gross margin	—	99.8%	5.3%	—	96.2%	12.2%	10.6%	12.6%	-272.8%	—	—	100.0%	—	—	—	87.1%	91.1%	91.8%	88.0%	89.0%	89.0%	90.2%	88.8%	88.9%	87.5%	87.5%	86.8%	88.4%	88.7%	90.3%	90.8%	89.8%	90.3%	89.9%	88.5%	85.3%	88.1%	91.3%	91.9%	90.9%
Operating margin	—	4.5%	-18621.0%	—	-3.9%	-3106.4%	-2835.8%	-5064.3%	-7451.9%	—	—	-131961.1%	—	—	—	-8548.4%	-841.5%	-342.1%	-348.9%	-175.1%	-206.5%	-123.1%	-161.9%	-112.7%	-112.4%	-112.1%	-128.2%	-72.8%	-64.7%	-62.1%	-137.1%	-118.3%	-69.6%	-112.6%	-182.3%	-171.2%	-99.7%	-50.5%	-39.8%	0.1%
Net margin	—	-11.1%	-17984.2%	—	-3.8%	-3084.4%	-2782.1%	-4952.2%	-7255.5%	—	—	-124872.2%	—	—	—	-8427.1%	-832.6%	-383.2%	-346.5%	-201.2%	-266.1%	-175.9%	-209.3%	-160.8%	-160.5%	-159.6%	-175.7%	-114.2%	-104.9%	-110.6%	-171.9%	-152.9%	-93.9%	-152.7%	-216.5%	-206.2%	-121.3%	-69.7%	-46.3%	-19.8%

Returns & leverage

Quarterly · %

ROE -1481.3% ROA -42.3% Debt ratio 152.4%

ROE / ROA = trailing four-quarter net income ÷ average equity / total assets (annual mode: the year’s net income ÷ average of opening and closing). Not computed when the denominator is zero or negative.

Show table：Returns & leverage

Item	2015Q4	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
ROE	—	—	—	-32.7%	-25.6%	-47.2%	-43.7%	-44.5%	-69.0%	-95.4%	-46.1%	-52.1%	-57.2%	-77.8%	-62.3%	-71.0%	-82.6%	-92.9%	-102.8%	-112.1%	-148.5%	-211.6%	-381.3%	-1481.3%	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
ROA	—	—	—	—	—	-40.6%	-23.2%	-34.4%	-55.1%	-84.5%	-43.9%	-49.0%	-53.0%	-68.7%	-58.0%	-65.2%	-74.7%	-79.2%	-88.2%	-70.8%	-82.3%	-91.7%	-86.1%	-75.8%	-83.1%	-86.0%	-80.1%	-90.3%	-65.3%	-65.1%	-66.5%	-60.2%	-46.6%	-54.7%	-61.8%	-63.2%	-67.6%	-63.1%	-53.1%	-42.3%
Debt ratio	—	29.3%	—	—	—	9.3%	4.3%	6.5%	8.0%	13.0%	4.9%	5.8%	7.0%	10.9%	9.9%	11.4%	13.8%	21.0%	21.5%	63.4%	76.6%	93.0%	110.3%	128.0%	149.3%	165.9%	203.2%	245.2%	121.7%	136.6%	120.0%	89.2%	91.5%	103.1%	118.8%	144.7%	162.4%	152.6%	149.0%	152.4%

Revenue & profit

Year-to-date · In mn (USD)

Revenue 123 mn Net income -37.9 mn

Year-to-date = summed from the first quarter of the fiscal year; balance-sheet items are period-end balances.

Balance sheet

Year-to-date · In mn (USD)

Total assets 253 mn Total liabilities 385 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Cash flow

Year-to-date · In mn (USD)

Operating -78.3 mn Investing -19.0 mn Financing 65.7 mn

Positive = cash in, negative = cash out.

Profitability

Year-to-date · %

Gross margin 91.3% Operating margin -16.3% Net margin -30.7%

Gross, operating and net margin = the respective profit ÷ revenue.

Returns & leverage

Year-to-date · %

ROE -1481.3% ROA -42.3% Debt ratio 152.4%

Revenue & profit

Annual · In mn (USD)

Revenue 110 mn Net income -153 mn

Annual = sum of four quarters of a complete fiscal year (incomplete years are omitted); balance-sheet items are year-end balances.

Show table：Income statement

Item	2017	2018	2019	2020	2021	2022	2023	2024	2025
Revenue	8.16	1.13	—	—	48.0	64.4	82.7	90.4	110
Gross profit	7.56	-0.67	—	—	42.9	56.7	73.3	81.5	97.3
Operating income	-19.9	-77.2	-109	-127	-92.3	-79.0	-65.5	-96.8	-125
Net income	-20.0	-75.7	-105	-128	-111	-110	-102	-127	-153

Balance sheet

Annual · In mn (USD)

Total assets 200 mn Total liabilities 306 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Show table：Balance sheet

Item	2017	2018	2019	2020	2021	2022	2023	2024	2025
Current assets	74.5	102	149	116	114	129	169	276	186
Total assets	75.5	104	202	122	120	136	178	286	200
Current liabilities	7.04	13.5	19.5	21.4	22.4	23.9	31.2	46.0	46.4
Total liabilities	7.04	13.5	22.1	25.6	111	225	244	295	306
Equity	68.5	90.1	180	96.4	8.41	-89.4	-65.2	-8.80	-105

Cash flow

Annual · In mn (USD)

Operating -162 mn Investing 61.6 mn Financing 39.9 mn

Positive = cash in, negative = cash out.

Show table：Cash flow statement

Item	2017	2018	2019	2020	2021	2022	2023	2024	2025
Operating	-9.57	-37.3	-71.0	-106	-84.9	-87.6	-76.4	-96.8	-162
Investing	-36.4	35.3	-146	93.2	4.07	1.06	-0.95	-20.6	61.6
Financing	61.6	66.4	165	16.5	72.3	97.1	117	195	39.9
Cash at period end	37.0	101	49.7	52.9	44.4	55.4	95.0	172	111

Profitability

Annual · %

Gross margin 88.7% Operating margin -113.7% Net margin -139.8%

Gross, operating and net margin = the respective profit ÷ revenue.

Show table：Profitability

Item	2017	2018	2019	2020	2021	2022	2023	2024	2025
Gross margin	92.7%	-59.8%	—	—	89.3%	88.1%	88.7%	90.2%	88.7%
Operating margin	-244.6%	-6842.2%	—	—	-192.1%	-122.8%	-79.2%	-107.1%	-113.7%
Net margin	-245.2%	-6707.2%	—	—	-230.7%	-170.6%	-123.6%	-140.3%	-139.8%

Returns & leverage

Annual · %

ROE -211.6% ROA -63.1% Debt ratio 152.6%

Show table：Returns & leverage

Item	2017	2018	2019	2020	2021	2022	2023	2024	2025
ROE	-29.2%	-95.4%	-77.8%	-92.9%	-211.6%	—	—	—	—
ROA	-26.5%	-84.5%	-68.7%	-79.2%	-91.7%	-86.0%	-65.1%	-54.7%	-63.1%
Debt ratio	9.3%	13.0%	10.9%	21.0%	93.0%	165.9%	136.6%	103.1%	152.6%

Source: SEC EDGAR (XBRL company facts)

Annual reports by year

	10-K
2025	Open full text →
2024	Open full text →
2023	Open full text →

10-K: annual report of a US domestic issuer. Filings are the original documents hosted on SEC EDGAR — this site neither mirrors nor edits them.

FAQ

Where can I read UroGen Pharma Ltd. (URGN) annual reports?

Every year in the table above links straight to the full text on SEC EDGAR. US annual reports are web pages (HTML) rather than PDFs, so you can read and search them in the browser without downloading anything. 3 filings are currently indexed.

What is the difference between a 10-K and a 20-F?

A 10-K is the annual report of a US domestic issuer, with sections fixed by law: Item 1 Business, Item 1A Risk Factors, Item 7 Management's Discussion and Analysis. A 20-F is filed by foreign private issuers — Taiwanese companies with US ADRs, such as TSMC, file 20-F rather than 10-K. A 40-F applies to Canadian issuers under the MJDS.

Are earnings call materials available here?

No. Earnings calls are not SEC filings, so US pages on this site cover annual reports only. Taiwan has a mandatory investor-conference disclosure regime, and those materials are indexed under Annual Reports.

Source: US Securities and Exchange Commission (SEC) EDGAR. This site indexes public filings and links to them; it hosts no copies, offers no investment advice, and makes no warranty as to timeliness or completeness.
Back to US annual reports, or see the supply-chain maps.